Key result
Point-of-care DOAC Dipstick yields accurate, uncomplicated results in ~91% of acute stroke patients.
Why the study?
In patients with acute stroke, plasma DOAC concentrations must be known for treatment decisions, prompting evaluation of the DOAC Dipstick point-of-care urine test.
Is the DOAC Dipstick a feasible and accurate point-of-care test for detecting DOACs in the urine of patients presenting with acute stroke or TIA?
Cohort (n=66)
Investigators evaluating visual results were blinded to semi-automated reader results and vice versa
Yes
Is the DOAC Dipstick a feasible and accurate point-of-care test for detecting DOACs in the urine of patients presenting with acute stroke or TIA?
Answers are grounded in this paper and cite their sources.
The DOAC Dipstick point-of-care test is highly feasible and accurate in an acute stroke setting, potentially aiding rapid decision-making regarding thrombolysis and DOAC reversal.
Background In patients with acute stroke, the plasma concentrations of direct oral anticoagulants (DOACs) need to be known for further treatment decisions. The point-of-care test DOAC Dipstick contains two test pads that determine levels of direct factor Xa (FXA) inhibitors and thrombin (THR) inhibitors in urine samples; thereby determining DOAC plasma levels of > 30 ng/mL within 10 minutes. Aim This study aimed to test the feasibility of using the DOAC Dipstick to detect the presence of DOACs in patients with acute stroke and transient ischemic attack (TIA) during the early phase of intrahospital stroke management. Methods Urine samples from patients with acute stroke and TIA with or without DOAC intake were obtained within 8 hours after hospitalisation. The urine samples were tested using the DOAC Dipstick. After incubation, colour change on the DOAC Dipstick pads were analysed visually and using a semi-automated reader. Primary endpoints were the success rate of evaluable pad results and time to results after urine sampling. Results From January 2023 to April 2024, 70 patients were recruited, 66 of whom fulfilled the inclusion criteria (39% female, mean age 73 ± 11.9 years). The median (interquartile range) times from urine sample collection to visual and reader test pad results were 20 (15–26) mins and 24 (16–37) mins, respectively. The test procedure was uncomplicated in most patients (n = 60). Complications in the test procedure were delays in urine sampling (n = 3), need for repeated testing due to dry strip (n = 2), no visual evaluability of the test result (n = 1), and abnormal urine colour (n = 1). The urine samples of all patients with prior DOAC intake (n = 26) were positive for DOACs while those for all patients without prior DOAC intake (n = 39) were negative for DOACs (one patient was excluded because the urine sample was not collected in time). Conclusion The DOAC Dipstick rapidly and reliably detects DOACs in urine samples from patients with acute stroke and TIA
No takes yet. Share an insight, caveat, or question.
Ziegler et al. (2026) conducted a cohort in Acute stroke and transient ischemic attack (TIA) (n=66). DOAC Dipstick point-of-care testing vs. Visual versus semi-automated reading / Prior DOAC intake history was evaluated on Success rate of evaluable pad results. The DOAC Dipstick point-of-care test was feasible with an uncomplicated test procedure in 90.9% of acute stroke and TIA patients, delivering accurate visual results in a median of 20 minutes.
Synapse has enriched 10 related papers. Consider them for comparative context: